Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Cash Flow: 2018-2025

Historic Net Cash Flow for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to -$16.1 million.

  • Arcturus Therapeutics Holdings' Net Cash Flow rose 30.43% to -$16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.8 million, marking a year-over-year increase of 24.23%. This contributed to the annual value of -$55.0 million for FY2024, which is 21.94% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Net Cash Flow of -$16.1 million as of Q3 2025, which was up 21.36% from -$20.5 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Cash Flow ranged from a high of $154.2 million in Q4 2022 and a low of -$63.9 million during Q1 2023.
  • Its 3-year average for Net Cash Flow is -$14.2 million, with a median of -$20.1 million in 2025.
  • Over the last 5 years, Arcturus Therapeutics Holdings' Net Cash Flow had its largest YoY gain of 455.47% in 2022, and its largest YoY loss of 1,388.39% in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Net Cash Flow stood at -$43.4 million in 2021, then skyrocketed by 455.47% to $154.2 million in 2022, then crashed by 113.07% to -$20.2 million in 2023, then spiked by 99.26% to -$150,000 in 2024, then soared by 30.43% to -$16.1 million in 2025.
  • Its Net Cash Flow was -$16.1 million in Q3 2025, compared to -$20.5 million in Q2 2025 and -$20.1 million in Q1 2025.